Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00297492 · ClinicalTrials.gov registry record · Phase 2
Gradual vs. Abrupt Cessation Treatment for Smoking
A Phase 2 study, sponsored by University of Vermont.
- Completed
- Registry status
- Phase 2
- Development phase
- 750
- Enrollment target
NCT00297492: Completed Phase 2 study, sponsored by University of Vermont.
NCT00297492 is a Phase 2 study that has completed, run by University of Vermont. The registered enrollment target is 750 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (464% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00297492, a Phase 2 study, has completed, sponsored by University of Vermont.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 750 participants
- Enrollment target
Study Summary
This study tests whether stopping smoking by gradually cutting down first is more or less successful than stopping abruptly. We hypothesize that stopping by gradually cutting down first will produce more abstinence than stopping abruptly.
Primary Outcome
Number of participants with self-reported prolonged abstinence from cigarette smoking through 6 months of follow-up, verified by a breath carbon monoxide reading of less than 10 parts per million
Interventions
- BEHAVIORAL Reduction Phone Counseling
- BEHAVIORAL Abrupt Phone Counseling
- BEHAVIORAL Minimal Abrupt Phone Counseling
- DRUG Pre-Quit Nicotine Lozenges
- DRUG Post-Quit Nicotine Lozenges
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2006-01 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
What the finished NCT00297492 record still lists
NCT00297492 is an interventional study that assigns participants to a tested intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (464% higher).
The record links to 0 conditions, and to 5 interventions - of which Reduction Phone Counseling is the first listed.
NCT00297492 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00297492 about?
NCT00297492 is a clinical study titled "Gradual vs. Abrupt Cessation Treatment for Smoking". This study tests whether stopping smoking by gradually cutting down first is more or less successful than stopping abruptly. We hypothesize that stopping by gradually cutting down first will produce more abstinence than stopping abruptly.
What is the current status of trial NCT00297492?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 750 participants. The study started on 2006-01. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00297492?
The interventions under investigation include: Reduction Phone Counseling (BEHAVIORAL), Abrupt Phone Counseling (BEHAVIORAL), Minimal Abrupt Phone Counseling (BEHAVIORAL), Pre-Quit Nicotine Lozenges (DRUG), Post-Quit Nicotine Lozenges (DRUG).
Who is sponsoring clinical trial NCT00297492?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00297492's enrollment target sits among peer trials
750 43rd of 2000 higher than 1,957 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia